SUCCESSFUL PROOF
OF CONCEPT STUDY
COMPLETED

RELEASE DATE: August 17 2020

Recent pre-clinical in-vivo Proof-of-Concept (POC) studies of Cancelex’s NCEs have been very successful with measurable dosage efficacy and tumor suppression properties of up to 50% above benchmark products.

POC testing data is confidential pending further patent filings but results are available to collaboration and investment partners.

The company invites collaboration in order to accelerate and complete POC studies in preparation for stage 1 clinical trials.

Parties interested in investments or further collaborations may contact us for more information. www.cancelex.com
info@moexa.com